Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

59 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Health-related quality-of-life in people living with HIV after switching to dual therapy with ritonavir-boosted darunavir + dolutegravir: a DUALIS sub-study.
Olliges E, Bührlen B, Fischer F, Boesecke C, Kümmerle T, Schneider J, Weidlich S, Cordes C, Heiken H, Stellbrink HJ, Krznaric I, Scholten S, Jensen BE, Wolf E, Ronel J, Spinner CD, On Behalf Of The Dualis Study Group. Olliges E, et al. Among authors: heiken h. AIDS Care. 2022 Jun;34(6):698-707. doi: 10.1080/09540121.2021.1916873. Epub 2021 Apr 25. AIDS Care. 2022. PMID: 33896276 Free article. Clinical Trial.
Switching to a NRTI-free 2 drug regimen (2DR) -a sub-analysis of the 48 weeks DUALIS study on metabolic and renal changes.
Monin M, Kümmerle T, Schneider J, Cordes C, Heiken H, Stellbrink HJ, Krznaric I, Scholten S, Jensen B, Jessen H, Obst W, Spornraft-Ragaller P, Khaykin P, Balogh A, Wolf E, Bidner H, Spinner CD, Boesecke C; DUALIS STUDY GROUP. Monin M, et al. Among authors: heiken h. HIV Res Clin Pract. 2021 Dec 23;23(1):15-21. Epub 2022 Mar 2. HIV Res Clin Pract. 2021. PMID: 35234092 Clinical Trial.
Efficacy and Safety of Switching to Dolutegravir With Boosted Darunavir in Virologically Suppressed Adults With HIV-1: A Randomized, Open-Label, Multicenter, Phase 3, Noninferiority Trial: The DUALIS Study.
Spinner CD, Kümmerle T, Schneider J, Cordes C, Heiken H, Stellbrink HJ, Krznaric I, Scholten S, Jensen B, Wyen C, Viehweger M, Lehmann C, Sprinzl M, Stoehr A, Bickel M, Jessen H, Obst W, Spornraft-Ragaller P, Khaykin P, Wolf E, Boesecke C; DUALIS Study Group. Spinner CD, et al. Among authors: heiken h. Open Forum Infect Dis. 2020 Aug 13;7(9):ofaa356. doi: 10.1093/ofid/ofaa356. eCollection 2020 Sep. Open Forum Infect Dis. 2020. PMID: 32965277 Free PMC article.
[Cost of Illness of HIV Patients under Anteretroviral Therapy in Germany - Results of the 48-Week Interim Analysis of the Prospective Multicentre Observational Study 'CORSAR'].
Kuhlmann A, Mittendorf T, Hower M, Heiken H, Gerschmann S, Klauke S, Lutz T, Bogner J, Degen O, van Lunzen J, Bachmann C, Stellbrink HJ, Schmidt W, Leistner I, Mahlich J, Ranneberg B, Stoll M. Kuhlmann A, et al. Among authors: heiken h. Gesundheitswesen. 2015 Jun;77(6):e133-42. doi: 10.1055/s-0034-1381993. Epub 2014 Sep 23. Gesundheitswesen. 2015. PMID: 25247761 German.
A Multicenter, Open Labeled, Randomized, Phase III Study Comparing Lopinavir/Ritonavir Plus Atazanavir to Lopinavir/Ritonavir Plus Zidovudine and Lamivudine in Naive HIV-1-Infected Patients: 48-Week Analysis of the LORAN Trial.
Ulbricht KU, Behrens GM, Stoll M, Salzberger B, Jessen H, Jessen AB, Kuhlmann B, Heiken H, Trein A, Schmidt RE. Ulbricht KU, et al. Among authors: heiken h. Open AIDS J. 2011;5:44-50. doi: 10.2174/1874613601105010044. Epub 2011 Apr 22. Open AIDS J. 2011. PMID: 21643422 Free PMC article.
59 results